Aptevo Therapeutics Inc
APVOAptevo Therapeutics Inc. is a biotechnology company focused on developing innovative immuno-oncology and hematology therapies. The company specializes in leveraging its proprietary ADAPTIR® bispecific antibody platform to create treatments aimed at improving outcomes for patients with cancer and blood disorders. Founded with a focus on immunotherapy, Aptevo integrates advanced scientific research with clinical development to address unmet medical needs.
Company News
Aptevo Therapeutics reported a net loss of $8.40 per share in Q2 2025, significantly better than analyst estimates. The company's lead bispecific antibody, mipletamig, showed promising 85% remission rates in acute myeloid leukemia trials, and raised $15.9 million in equity to extend its cash runway.
Bloom Energy shares jumped 12.1% after announcing a strategic partnership with CoreWeave to deploy its fuel cells for on-site power generation at a data center. Several other stocks also saw significant pre-market movements, both positive and negative.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Groupon (GRPN), Aptevo Therapeutics (APVO), NewJersey Resources (NJR), American Water Works (AWK) and Frontdoor (FTDR).
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
